AlphaCentric Advisors LLC Has $1.17 Million Stake in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

AlphaCentric Advisors LLC increased its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 29.4% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 11,000 shares of the specialty pharmaceutical company’s stock after buying an additional 2,500 shares during the period. AlphaCentric Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $1,174,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Fifth Third Wealth Advisors LLC acquired a new position in Jazz Pharmaceuticals in the second quarter worth approximately $206,000. Hennion & Walsh Asset Management Inc. boosted its position in Jazz Pharmaceuticals by 16.6% during the second quarter. Hennion & Walsh Asset Management Inc. now owns 29,447 shares of the specialty pharmaceutical company’s stock worth $3,143,000 after purchasing an additional 4,183 shares during the period. Greylin Investment Management Inc bought a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $966,000. Gladius Capital Management LP bought a new stake in Jazz Pharmaceuticals during the second quarter worth approximately $33,000. Finally, Blue Trust Inc. boosted its position in Jazz Pharmaceuticals by 24.5% during the second quarter. Blue Trust Inc. now owns 1,307 shares of the specialty pharmaceutical company’s stock worth $139,000 after purchasing an additional 257 shares during the period. Institutional investors and hedge funds own 89.14% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have issued reports on JAZZ. Wells Fargo & Company decreased their target price on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a research report on Thursday, August 1st. HC Wainwright reissued a “buy” rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a research report on Thursday, August 1st. Piper Sandler reduced their price objective on Jazz Pharmaceuticals from $188.00 to $166.00 and set an “overweight” rating for the company in a research report on Thursday, August 1st. JPMorgan Chase & Co. raised their target price on Jazz Pharmaceuticals from $190.00 to $202.00 and gave the stock an “overweight” rating in a research report on Monday, August 19th. Finally, Barclays reduced their target price on Jazz Pharmaceuticals from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Friday, May 3rd. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Jazz Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $173.07.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ traded up $0.42 during midday trading on Monday, reaching $114.29. The company’s stock had a trading volume of 321,578 shares, compared to its average volume of 667,764. Jazz Pharmaceuticals plc has a fifty-two week low of $99.06 and a fifty-two week high of $146.70. The company has a market capitalization of $7.21 billion, a P/E ratio of 23.72, a P/E/G ratio of 1.76 and a beta of 0.58. The company has a debt-to-equity ratio of 1.36, a current ratio of 2.37 and a quick ratio of 1.90. The business’s fifty day simple moving average is $109.11 and its 200-day simple moving average is $112.99.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.